Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Sumitomo Dainippon Pharma Co. Ltd.
DescriptionInhibitor of voltage-gated sodium channels Nav1.7 and Nav1.8
Molecular Target Nav1.7 (SCN9A) ; Nav1.8 (PN3) (SCN10A)
Mechanism of ActionNa channel blocker
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationPain
Indication DetailsTreat neuropathic pain
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today